ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Opdivo, Yervoy Combination Study Meets Co-Primary Endpoint americanpharmaceuticalreview
July 26, 2019Bristol-Myers Squibb announced Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo? (nivolumab) plus low-dose Yervoy? (ipilimumab) met the co-primary endpoint of overall survival (OS) ...
Pharma Sources Insight January 2025
